Financial PerformanceSales and adjusted EBITDA were both $6 million ahead of estimates supported by beats in core lymphedema and especially AffloVest that was up 71%.
Growth InitiativesKey efforts benefiting growth include an expanded salesforce, an improved CRM, and pilot efforts like patient engagement and AI salesforce productivity software—all of which are compounding for improved growth benefits.
Market ConfidenceShares are up over 20% after hours on an accelerating quarter and a strong balance sheet that lends credibility to the relatively new management team’s commercial efforts.